Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy

Andrea Antinori, speaking at HIV Glasgow. Image courtesy of HIV Drug Therapy Glasgow 2014 (
Keith Alcorn
Published: 07 November 2014

Darunavir/ritonavir monotherapy results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs), but may be just as effective as three-drug therapy in people with nadir (lowest-ever) CD4 cell counts above 200, according to a 48-week analysis of the PROTEA study presented on Thursday at the HIV Drug Therapy Glasgow conference.

Monotherapy with a boosted protease inhibitor has been proposed as a form of maintenance therapy in people who have achieved viral load suppression, as a means of reducing toxicity and cost whilst preserving future treatment options in the event of virological rebound.

Monotherapy with a ritonavir-boosted protease inhibitor has been evaluated in numerous studies of lopinavir/ritonavir, atazanavir/ritonavir and darunavir/ritonavir. A meta-analysis and review of ten studies of protease inhibitor monotherapy found a lower rate of viral suppression (76% vs 82%) but no increased risk of drug resistance in the monotherapy arm in these studies (Arribas 2014).

The largest study of boosted protease inhibitor monotherapy, PIVOT, conducted in the United Kingdom by the Medical Research Council, randomised 587 people to continue a three-drug regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI), or to switch to a boosted protease inhibitor chosen by patient and clinician. In that study, 79% of the participants in the monotherapy arm took darunavir/ritonavir. After five years of follow-up, 32% of participants in the monotherapy arm had to return to taking a three-drug regimen in order to re-suppress viral load, but despite the higher rate of viral rebound in the monotherapy arm, the study found no significant difference in the rate at which participants lost future treatment options as a consequence of developing drug resistance. Since loss of future drug options was the primary endpoint in the PIVOT study, the strategy of boosted PI monotherapy was found to be non-inferior. However, in the three-drug arm only 3.2% of participants experienced viral rebound (Paton 2014).

A health economic analysis of PIVOT presented to HIV Glasgow by Simon Walker of York University showed that protease inhibitor monotherapy was cost-effective compared to three-drug therapy and cost-saving (Oddershede 2014).

PROTEA study of darunavir / ritonavir

The PROTEA study randomised 273 people on stable antiretroviral therapy with suppressed viral load to either darunavir/ritonavir monotherapy or darunavir/ritonavir plus two NRTIs. The study population had been taking antiretroviral therapy for an average of just over five years and had a median CD4 cell count of 593 cells/mm3 in the monotherapy arm and 623 in the triple therapy arm. 29.9% of the monotherapy group and 22.1% of the triple therapy arm had had a lowest-ever CD4 count prior to treatment below 200 cells/mm3.

The primary efficacy endpoint of the study was the proportion of participants with viral load below 50 copies/ml at week 48, with patients who had switched from their initially assigned regimen for any reason counted as virologic failures. 86.1% in the darunavir monotherapy arm and 94.9% in the triple therapy arm had viral load below 50 copies/ml by this intent-to-treat analysis. Although this difference did not meet the criterion for inferiority, the efficacy of darunavir/ritonavir monotherapy was described as lower by Andrea Antinori of the National Institute of Infectious Diseases, Rome, when presenting the results.

A post-hoc analysis (not part of the original study design) found no difference in efficacy between the two arms in people with lowest-ever CD4 cell counts above 200 (94.8 vs 94.3%) (202 participants) but a substantial difference in efficacy in those with a lowest-ever CD4 cell count below 200 (65.9 vs 96.7%) (71 participants) favouring triple therapy.

Darunavir/ritonavir monotherapy was associated with a slightly higher rate of treatment-emergent adverse events. Due to lower penetration of protease inhibitors into the cerebrospinal fluid, 40 particpants underwent CSF sampling at baseline and week 48 in order to evaluate viral load in CSF. One person in the darunavir monotherapy arm had detectable HIV in CSF (654 copies/ml) and in plasma (77 copies/ml) at week 48. One person in the darunavir monotherapy arm, not enrolled in the CSF sub-study, developed HIV encephalomyelitis at week 24 with a CSF viral load of 2500 copies/ml and plasma viral load of 500 copies/ml. Viral load was resuppressed and symptoms resolved after two NRTIs were added.


Antinori A et al. Week 48 efficacy analysis of the PROTEA trial: darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL at baseline. J Int AIDS Soc 17 (suppl 3): 24 (abstract 0423A), 2014.

Arribas J et al. Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. J Int AIDS Soc 17 (suppl 3): 181 (abstract P256), 2014.

Clarke A et al. Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues. J Int AIDS Soc 17 (suppl 3): 25 (abstract 0423B), 2014.

Paton N et al. Randomised controlled trial of a PI monotherapy switch strategy for long-term HIV management. 21st Conference on Retroviruses and Opportunistic Infections, Boston, abstract 550LB, 2014.

Oddershede L et al. Cost-effectiveness analysis of protease inhibitor monotherapy vs ongoing triple therapy in the long-term management of HIV patients. J Int AIDS Soc 17 (suppl 3): 9 (abstract 0217), 2014.

NAM's conference news reporting services have been made possible thanks to support from Merck & Co., Inc., Bristol-Myers Squibb and the Organising Committee of HIV Drug Therapy Glasgow.​

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.